NASDAQ:NRXS NeurAxis (NRXS) Stock Price, News & Analysis → The ONE AI Stock to own now. (It’s not Nvidia.) (From Weiss Ratings) (Ad) Free NRXS Stock Alerts $3.04 -0.05 (-1.62%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$2.70▼$3.0850-Day Range$2.76▼$3.5952-Week Range$1.80▼$6.93Volume15,349 shsAverage Volume9,213 shsMarket Capitalization$20.03 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsSocial Media Get NeurAxis alerts: Email Address Ad Stansberry ResearchA letter is coming from the "Bureau of the Fiscal Service".Is your bank next? A powerful new trend is spreading like wildfire inside the US financial system. At least 41 banks are already involved. But the Federal Reserve predicts that number will grow fast.See if your bank is involved right here. About NeurAxis Stock (NASDAQ:NRXS)NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.Read More NRXS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NRXS Stock News HeadlinesMay 19 at 1:34 AM | americanbankingnews.comAnalyzing NeurAxis (NRXS) and Its CompetitorsMay 18 at 1:21 AM | americanbankingnews.comHead to Head Comparison: NeurAxis (NRXS) and Its CompetitorsMay 17 at 3:42 AM | americanbankingnews.comHead to Head Comparison: NeurAxis (NRXS) and Its PeersMay 17 at 2:28 AM | americanbankingnews.comReviewing NeurAxis (NRXS) and Its RivalsMay 17 at 1:56 AM | americanbankingnews.comHead to Head Analysis: NeurAxis (NRXS) vs. Its CompetitorsMay 16 at 12:00 PM | finance.yahoo.comNeurAxis Announces New Medical Policy Coverage For Nearly Six Million Lives in FloridaMay 15, 2024 | globenewswire.comNeurAxis to Host First Quarter 2024 Results and Business Update Call on Wednesday, May 22, 2024May 12, 2024 | americanbankingnews.comNeurAxis (NRXS) versus Its Peers Critical ReviewApril 23, 2024 | globenewswire.comNeurAxis Announces New Medical Policy Coverage in North DakotaApril 12, 2024 | finance.yahoo.comNeurAxis, Inc. (NASDAQ:NRXS) Q4 2023 Earnings Call TranscriptApril 11, 2024 | finanznachrichten.deNeurAxis, Inc.: NeurAxis Reports Fourth Quarter and Fiscal Year 2023 Financial ResultsApril 11, 2024 | seekingalpha.comNeurAxis, Inc. (NRXS) Q4 2023 Earnings Call TranscriptApril 9, 2024 | globenewswire.comNeurAxis Reports Fourth Quarter and Fiscal Year 2023 Financial ResultsApril 1, 2024 | globenewswire.comNeurAxis to Host Fourth Quarter and Full Year 2023 Results and Business Update Call on Tuesday, April 9, 2024March 27, 2024 | globenewswire.comNeurAxis Announces IB-Stim Results from a Large, Pediatric, Multi-Center RegistryMarch 11, 2024 | globenewswire.comNeurAxis Announces Highmark BCBS Policy CoverageMarch 4, 2024 | globenewswire.comNeurAxis Announces Blue Cross and Blue Shield of Kansas City Policy CoverageFebruary 27, 2024 | globenewswire.comNeurAxis to Present at Oppenheimer 34th Annual Healthcare MedTech & Services ConferenceFebruary 1, 2024 | au.finance.yahoo.comNeurAxis, Inc. (NRXS)January 31, 2024 | finanznachrichten.deNeurAxis, Inc.: NeurAxis Appoints Timothy Henrichs as Chief Financial OfficerJanuary 31, 2024 | finance.yahoo.comNeurAxis Appoints Timothy Henrichs as Chief Financial OfficerDecember 20, 2023 | finanznachrichten.deNeurAxis, Inc. Issues Letter to Shareholders from Brian Carrico, President and Chief Executive OfficerDecember 20, 2023 | finance.yahoo.comNeurAxis, Inc. Issues Letter to Shareholders from Brian Carrico, President and Chief Executive OfficerNovember 21, 2023 | finanznachrichten.deNeurAxis, Inc.: NeurAxis Reports Third Quarter 2023 Financial ResultsNovember 21, 2023 | msn.comNeurAxis reports Q3 resultsSee More Headlines Receive NRXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeurAxis and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/16/2024Today5/19/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Electromedical equipment Sub-IndustryN/A Current SymbolNASDAQ:NRXS CUSIPN/A CIK1933567 Webneuraxis.com Phone(812) 689-0791FaxN/AEmployees17Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($4.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,630,000.00 Net Margins-594.55% Pretax Margin-594.59% Return on EquityN/A Return on Assets-899.27% Debt Debt-to-Equity RatioN/A Current Ratio0.13 Quick Ratio0.12 Sales & Book Value Annual Sales$2.46 million Price / Sales8.14 Cash FlowN/A Price / Cash FlowN/A Book Value($0.27) per share Price / Book-11.26Miscellaneous Outstanding Shares6,590,000Free FloatN/AMarket Cap$20.03 million OptionableNot Optionable BetaN/A A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Brian Carrico (Age 42)President, CEO & Director Comp: $373.58kDr. Adrian Miranda (Age 54)Senior VP of Science & Technology and Chief Medical Officer Comp: $266.35kDr. Christopher Robin Brown D.D.S. (Age 70)Founder, Director of Innovation & Director Key CompetitorsQT ImagingNASDAQ:QTIBioSig TechnologiesNASDAQ:BSGMPixie Dust TechnologiesNASDAQ:PXDTPrecision OpticsNASDAQ:POCIMovanoNASDAQ:MOVEView All Competitors NRXS Stock Analysis - Frequently Asked Questions Should I buy or sell NeurAxis stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NeurAxis in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" NRXS shares. View NRXS analyst ratings or view top-rated stocks. How have NRXS shares performed in 2024? NeurAxis' stock was trading at $2.67 at the beginning of the year. Since then, NRXS stock has increased by 13.9% and is now trading at $3.04. View the best growth stocks for 2024 here. How were NeurAxis' earnings last quarter? NeurAxis, Inc. (NASDAQ:NRXS) announced its earnings results on Tuesday, April, 16th. The company reported $0.29 earnings per share for the quarter. The company earned $0.53 million during the quarter. When did NeurAxis IPO? NeurAxis (NRXS) raised $7 million in an initial public offering (IPO) on Wednesday, August 9th 2023. The company issued 1,098,667 shares at $6.00 per share. How do I buy shares of NeurAxis? Shares of NRXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NRXS) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersShocking: One AI startup's revenue could surge 4,735%Manward PressShocking $16T Elon Musk Crypto LeakCrypto 101 MediaDems have chosen Biden replacement?Paradigm PressBiden Nomination CANCELED?The Freeport SocietyUrgent Nvidia WarningAltimetryMost important medical advance in 100 yearsThe Oxford ClubMissed NVDA? Buy this AI stock NOWChaikin Analytics41 banks launch ‘crypto dollar’Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeurAxis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
